Megan E Daly1, Navneet Singh2, Nofisat Ismaila3, Mara B Antonoff4, Douglas A Arenberg5, Jeffrey Bradley6, Elizabeth David7, Frank Detterbeck8, Martin Früh9,10, Matthew A Gubens11, Amy C Moore12, Sukhmani K Padda13, Jyoti D Patel14, Tanyanika Phillips15, Angel Qin5, Clifford Robinson16, Charles B Simone17. 1. University of California, Davis, CA. 2. Postgraduate Institute of Medical Education & Research, Chandigarh, India. 3. American Society of Clinical Oncology (ASCO), Alexandria, VA. 4. MD Anderson Cancer Center, Houston, TX. 5. University of Michigan, Ann Arbor, MI. 6. Emory University, Atlanta, GA. 7. University of Southern California, Los Angeles, CA. 8. Yale Cancer Center, New Haven, CT. 9. Department of Medical Oncology Cantonal Hospital of St Gallen, St Gallen, Switzerland. 10. University of Bern, Bern, Switzerland. 11. University of California, San Francisco, CA. 12. LUNGevity Foundation, Chicago, IL. 13. Department of Medicine, Division of Oncology, Cedars-Sinai Medical Center, Los Angeles, CA. 14. Northwestern University-Feinberg School of Medicine, Chicago, IL. 15. City of Hope, Lancaster, CA. 16. Washington University, St Louis, MO. 17. New York Proton Center and Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract
PURPOSE: To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non-small-cell lung cancer (NSCLC). METHODS: An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, community oncology, research methodology, and advocacy experts was convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2021. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 127 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations were developed to address evaluation and staging workup of patients with suspected stage III NSCLC, surgical management, neoadjuvant and adjuvant approaches, and management of patients with unresectable stage III NSCLC.Additional information is available at www.asco.org/thoracic-cancer-guidelines.
PURPOSE: To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non-small-cell lung cancer (NSCLC). METHODS: An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, community oncology, research methodology, and advocacy experts was convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2021. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 127 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations were developed to address evaluation and staging workup of patients with suspected stage III NSCLC, surgical management, neoadjuvant and adjuvant approaches, and management of patients with unresectable stage III NSCLC.Additional information is available at www.asco.org/thoracic-cancer-guidelines.